Business Context and Reporting Period
Company: Coherus BioSciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 21, 2016
Event: Entry into a Material Definitive Agreement (Lease Amendment)
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or general liquidity metrics. It discloses specific financial obligations related to a lease expansion:
- Expansion Space: Approximately 12,809 square feet (Total Premises: 40,341 square feet).
- Annual Base Rent (Expansion Space): Approximately $0.75 million in the first 12 months, increasing to approximately $0.87 million in the final 12 months of the term.
- Improvement Allowance: One-time allowance of approximately $0.19 million.
- Lease Term: Expansion term ends November 30, 2022, with an option to extend for one additional five-year period.
Material Changes
The Company amended its existing office lease to expand its principal executive offices in Redwood City, California. The amendment creates a direct financial obligation for increased rent, taxes, and operating expenses associated with the additional space, effective November 1, 2016, or upon earlier occupancy.
Outlook, Risks, and Management Commentary
Management Commentary: The filing indicates the Company is expanding its physical footprint to support operations. The lease includes limited rent abatements for the first five months of the expansion term.
Risks/Contingencies: The Company assumes increased fixed costs (rent and operating expenses) through 2022. The filing notes that the description of terms is qualified by the full agreement filed as Exhibit 10.1.
Investor Verification Checklist
- Verify the exact "Expansion Effective Date" to determine when rent obligations commence.
- Review Exhibit 10.1 for specific details on operating expense calculations and tax obligations.
- Confirm the utilization of the $0.19 million improvement allowance and its impact on cash flow.
- Assess the impact of the increased fixed lease costs on the Company's overall burn rate and liquidity position.